Actively Recruiting
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Led by Allist Pharmaceuticals, Inc. · Updated on 2025-04-04
104
Participants Needed
21
Research Sites
180 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
CONDITIONS
Official Title
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing.
- STK11 co-mutation and KEAP1 Wild-Type (local confirmation)
- Treatment naïve or have received at least 1 prior standard therapy for advanced NSCLC
- ECOG 0-1
You will not qualify if you...
- Has CNS metastases or carcinomatous meningitis, except treated CNS metastases with no evidence of radiographic progression or hemorrhage for at least 28 days
- Any severe and/or uncontrolled medical conditions
- Active infection requiring systemic treatment within 7 days
- Therapeutic radiation therapy within 3 weeks of study day 1
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Research site08
Beijing, Beijing Municipality, China, 100010
Not Yet Recruiting
2
Research site09
Beijing, Beijing Municipality, China, 100010
Not Yet Recruiting
3
Research site021
Beijing, Beijing Municipality, China, 100032
Not Yet Recruiting
4
Research site02
Beijing, Beijing Municipality, China, 100089
Not Yet Recruiting
5
Research site01
Beijing, Beijing Municipality, China, 100101
Actively Recruiting
6
Research site013
Beijing, Beijing Municipality, China, 101100
Not Yet Recruiting
7
Research site010
Chongqing, Chongqing Municipality, China, 400000
Not Yet Recruiting
8
Research site05
Xiamen, Fujian, China, 361000
Not Yet Recruiting
9
Research site011
Shenzhen, Guangdong, China, 518000
Not Yet Recruiting
10
Research site016
Nanning, Guangxi, China, 530000
Not Yet Recruiting
11
Research site017
Shijiazhuang, Hebei, China, 050000
Not Yet Recruiting
12
Research site018
Harbin, Heilongjiang, China, 150000
Not Yet Recruiting
13
Research site04
Zhengzhou, Henan, China, 450000
Not Yet Recruiting
14
Research site012
Changsha, Hunan, China, 410000
Not Yet Recruiting
15
Research site015
Changchun, Jilin, China, 130000
Not Yet Recruiting
16
Research site06
Shenyang, Liaoning, China, 110000
Not Yet Recruiting
17
Research site07
Shenyang, Liaoning, China, 110000
Not Yet Recruiting
18
Research site014
Hohhot, Neimenggu, China, 010000
Not Yet Recruiting
19
Research site020
Xi’an, Shanxi, China, 710000
Not Yet Recruiting
20
Research site03
Hubei, Wuhan, China, 430060
Not Yet Recruiting
21
Research site019
Hangzhou, Zhejiang, China, 310000
Not Yet Recruiting
Research Team
S
Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., Ltd
CONTACT
W
Wang Jie Wang Jie M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here